Core Viewpoint - The company reported its Q3 2025 results, showing a revenue increase of 25.5% year-on-year, with a net profit growth of 2.13% [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 2.45 billion yuan, with a net profit of 240 million yuan [1]. - In Q3 alone, revenue reached 690 million yuan, reflecting a 14.3% year-on-year growth, while net profit was 69.48 million yuan, up 11.6% year-on-year [1]. - The non-recurring net profit decreased by 20% year-on-year in Q3 [1]. Segment Performance - In Q3 2025, revenue by product category was as follows: eye care (150 million yuan, +20%), skincare (310 million yuan, +42%), cleansing (70 million yuan, +23%), and beauty products (150 million yuan, -27%) [2]. - The main brand is expected to maintain good growth, while the sub-brand "Lianhuo" is under pressure [2]. - Average prices for skincare products increased due to a higher sales proportion of eye care products and a decrease in lower-priced eye care product sales [2]. Profitability Analysis - For Q1-Q3 2025, the net profit margin decreased by 2.3 percentage points to 10% [2]. - Gross margin slightly increased by 0.3 percentage points to 74.9% [2]. - The increase in sales, management, and R&D expense ratios contributed to a total expense ratio increase of 3.1 percentage points [2]. Investment Outlook - The company continues to implement a big product strategy, with its two main brands, "Marubi" and "Lianhuo," showing sustained growth [3]. - New products like "Little Gold Needle Cream" and "Little Gold Needle Mask" are expected to contribute to growth [3]. - EPS forecasts for 2025, 2026, and 2027 are 0.95, 1.12, and 1.29 yuan per share, respectively, maintaining a "buy" rating [3].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - The company reported a revenue of 2.45 billion yuan for Q1-Q3 2025, representing a year-on-year growth of 25.5%. The net profit attributable to shareholders was 240 million yuan, up 2.13% year-on-year. In Q3 alone, revenue reached 690 million yuan, a 14.3% increase year-on-year, while net profit attributable to shareholders was 69.48 million yuan, growing by 11.6% year-on-year. However, the non-recurring net profit saw a decline of 20% year-on-year [2][4]. Summary by Sections Revenue Performance - For Q3 2025, the company achieved revenue of 1.5 billion yuan from eye care products, 3.1 billion yuan from skincare, 0.7 billion yuan from cleansing products, and 1.5 billion yuan from beauty products, with year-on-year growth rates of 20%, 42%, 23%, and -27% respectively. The main brand is expected to maintain good growth, while the beauty category is under pressure [9]. Profitability Analysis - In the first three quarters of 2025, the net profit margin decreased by 2.3 percentage points to 10%. This was attributed to a slight increase in gross margin by 0.3 percentage points to 74.9%, while sales, management, and R&D expense ratios increased by a total of 3.1 percentage points [9]. Investment Recommendations - The company is expected to continue its large product strategy, with the main brands, Marubi and Lianhuo, maintaining growth momentum. New products such as the "Little Gold Needle" cream and mask are being introduced, indicating significant growth potential. The forecasted EPS for 2025-2027 is 0.95, 1.12, and 1.29 yuan per share respectively, with a "Buy" rating maintained [9].

Investment Rating - The report maintains a "Positive" investment rating for the cosmetics industry [3] Core Insights - The cosmetics industry is experiencing stable growth with a slight improvement in growth rates, while profitability continues to show differentiation among companies [11][16] - The average revenue growth rate for the cosmetics industry in Q1 and Q2 of 2025 was -8.4% and -2.1%, respectively, indicating a slight improvement in the second quarter [16] - Online sales channels, particularly Tmall and Douyin, have shown a year-on-year growth of 13.1% in the first half of 2025, reflecting a recovery in consumer demand [11] Summary by Sections Cosmetics: Stable Growth and Business Adjustments - The cosmetics industry showed a year-on-year growth of 3.1% and 2.6% in Q1 and Q2 of 2025, respectively, with a significant improvement compared to the -1.1% growth in 2024 [11] - The industry is characterized by a slight improvement in growth rates, with the overall growth falling into a stable range [11] Revenue: Differentiation Among Brands - The average revenue growth for the brand segment was 0.4% and 6.5% in Q1 and Q2 of 2025, respectively, indicating stronger resilience compared to upstream and downstream segments [16] - Mid-sized brands like Maogeping and Shangmei have achieved good growth amidst a stable industry backdrop, while leading companies like Proya continue to grow steadily [16] Gross Margin Trends - The average gross margin for the brand segment increased by 1.6 percentage points in the first half of 2025, driven by improved business structures and effective price control by certain brands [21] - Specific brands like Water Sheep and Beitaini have seen significant improvements in gross margins due to product upgrades and price management strategies [21] Product Innovation: Focus on Core Series and Efficacy Expansion - Brands are focusing on upgrading core product lines and expanding efficacy categories, particularly in sunscreen and whitening, with increased competition expected [25] - New product launches include Proya's whitening series and Beitaini's anti-aging products, indicating a trend towards enhancing product offerings [25] Sales Expenses: Rising Industry Rates - The average sales expense ratio for brands in the first half of 2025 was 44.7%, reflecting a year-on-year increase of 1.7 percentage points, influenced by rising competition and platform costs [31] - The narrowing of gross sales margins indicates ongoing pressure on profitability across the industry [31]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company reported a revenue of 1.77 billion yuan for the first half of 2025, representing a year-on-year growth of 30.8%, while the net profit attributable to shareholders was 190 million yuan, up 5.2% year-on-year. In the second quarter alone, revenue reached 920 million yuan, with a year-on-year increase of 33.5%, but net profit fell by 23.1% year-on-year to 50 million yuan [2][4] Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 1.77 billion yuan, a 30.8% increase year-on-year, and a net profit of 190 million yuan, which is a 5.2% increase year-on-year. For the second quarter, revenue was 920 million yuan, reflecting a 33.5% year-on-year growth, while net profit decreased by 23.1% year-on-year to 50 million yuan [2][4][10] Brand and Product Strategy - The company continues to implement a big product strategy, with its main brands, Marubi and Lianhuo, achieving revenues of 1.25 billion yuan and 520 million yuan respectively in the first half of 2025, representing year-on-year growth of 34.4% and 23.9%. New products such as the small gold needle cream and small gold needle mask have been launched, contributing to the brand's ongoing expansion [10] Sales and Profitability - The company's net profit margin decreased by 2.6 percentage points to 10.5% in the first half of 2025, primarily due to a 3.4 percentage point increase in sales expenses. Although management and R&D expenses were optimized, the overall expense ratio still increased [10] Future Outlook - The company is expected to maintain its growth trajectory with projected earnings per share (EPS) of 1.06 yuan, 1.43 yuan, and 1.78 yuan for 2025, 2026, and 2027 respectively. The ongoing brand momentum and effective cost management are anticipated to support future profitability improvements [10]

Investment Rating - The report maintains a "Positive" investment rating for the beauty industry [3] Core Insights - The beauty industry is experiencing stable growth, with a notable performance in the collagen restructuring segment [1][5] - The overall revenue growth for the cosmetics sector has shown slight improvement, with a year-on-year increase of 3.1% in Q1 2025, recovering from previous negative growth [12][19] - The average revenue growth for the cosmetics industry is projected to be 8% in 2024, followed by a decline to -5% in Q1 2025, indicating a trend of increasing differentiation among brands [19] Summary by Sections Cosmetics - The cosmetics industry has shown a steady growth rate, with Q1 2025 marking a recovery from three consecutive quarters of negative growth [12] - Online sales channels, particularly Tmall and Douyin, have seen significant growth, with a combined increase of 17% in Q1 2025 [12] - The average revenue growth for brands has been more resilient compared to upstream and downstream segments, with mid-sized brands like Marubi and Runben achieving good growth despite a generally weak market [19] Medical Beauty - The medical beauty sector has seen a convergence in revenue, while the collagen restructuring segment continues to maintain high growth rates [1][5] Revenue and Profitability - The average revenue growth for the cosmetics industry has been declining, with a notable differentiation in performance among brands [19] - The average gross margin for the brand segment has slightly increased, attributed to improved business structure and price control measures [20] Product Innovation - Brands are focusing on upgrading main product lines and expanding functional categories, particularly in sun protection and whitening, with increased competition expected [25] - New product launches include significant upgrades in major brands like Proya and Bethany, focusing on whitening and sun protection [24][25] Expenses and Profit Margins - The average sales expense ratio for brands has increased, reflecting heightened competition and rising platform costs [26] - The gross profit margin has generally decreased across the industry, although leading brands like Proya have managed to improve their margins through effective cost management [26][35] R&D and Management Expenses - There is a trend of increasing R&D investment among leading brands, with a shift towards foundational research [45] - Management expense ratios have shown a divergence, with leading companies optimizing their expenses while others have seen increases due to business adjustments [45]